Elimination half-life

References

1. ^ 2020.
2. ^ 2020.
3. ^ 144. doi:10.1016/b978-0-12-079035-7.50015-4. ISBN . The elimination half-life measures the kinetics of loss of drug from the body as a whole once all distribution equilibria have been achieved.
4. ^ 17. doi:10.1016/b978-0-12-815849-4.00001-3. ISBN . S2CID 209258489. The half-life of a drug is the time required for the serum concentration to be reduced by 50%. Once the half-life of the drug is known, the time required for clearance can be estimated. Approximately 97% of the drug is eliminated by 5 halflives, while ~99% is eliminated by 7 half-lives.
5. ^ . Journal of Veterinary Pharmacology and Therapeutics. 27 (6): 427–439. doi:10.1111/j.1365-2885.2004.00600.x. PMID 15601438. Archived from the original(PDF) on 20 February 2020. Following i.v. administration, the terminal half-life is the time required for plasma/blood concentration to decrease by 50% after pseudo-equilibrium of distribution has been reached; then, terminal half-life is computed when the decrease in drug plasma concentration is due only to drug elimination, and the term 'elimination half-life' is applicable. Therefore, it is not the time necessary for the amount of the administered drug to fall by one half.
6. ^ 710. doi:10.1177/070674379003500811. PMID 1980860.
7. ^
8. ^
9. ^
10. ^
11. ^
12. ^
13. ^ 5. doi:10.1385/MO:19:4:261. PMID 12512920. S2CID 1068099. Archived from the original on 28 September 2007 2007.
14. ^ . Accessed 15 April 2021.
15. ^ . Accessed 15 April 2021.
16. ^ . Accessed 15 April 2021.
17. ^
18. ^ 2007.
19. ^ . Accessed 15 April 2021.
20. ^
21. ^ . Accessed 15 April 2021.
22. ^ . Genentech USA, Inc. October 2017. Archived from the original(PDF) on 26 May 2018 2019.
23. ^ 150. doi:10.1016/s1871-5125(10)35003-5. ISBN . ISSN 1871-5125. PMID 22469221. Plasma donepezil concentrations decline with a half-life of approximately 70 h. Sex, race, and smoking history have no clinically significant influence on plasma concentrations of donepezil [46–51].
24. ^ . Accessed 15 April 2021.
25. ^ 2014.
26. ^
27. ^ . Sanofi Genzyme, Cambridge, MA, Dec 2016 2020.
28. ^
29. ^ . Janssen Products, Dec 2012. Archived from the original(PDF) on 28 February 2013 2020.
30. ^
31. ^
32. ^
33. ^ . ISSN 1662-453X. PMC 4585313. PMID 26441508.
34. ^
35. ^ 68. doi:10.1038/bjp.2008.132. PMC 2442436. PMID 18475254. Recent studies also highlight remarkable anxiolytic and prosocial effects of intranasally administered OT in humans, including increased 'trust', decreased amygdala activation towards fear-inducing stimuli, improved recognition of social cues and increased gaze directed towards the eye regions of others (Kirsch et al., 2005; Kosfeld et al., 2005; Domes et al., 2006; Guastella et al., 2008)
36. ^ 6. doi:10.1016/j.psyneuen.2012.02.014. PMID 22436536. S2CID 25253083.
37. ^ 5. PMID 22467107.
38. ^
39. ^ 139. doi:10.1016/B978-0-323-54391-0.00011-4. ISBN . S2CID 57512164.
40. ^ 47. doi:10.1007/978-1-4614-8948-1_1. ISBN .
41. ^ 239. ISBN .
42. ^ 439. doi:10.1111/j.1365-2885.2004.00600.x. ISSN 0140-7783. PMID 15601438.
43. ^